Otlertuzumab · TRU-016

What is Otlertuzumab?

Otlertuzumab is a recombinant single-chain polypeptide engineered to retain the binding and activity of an anti-CD37 monoclonal antibody. It binds CD37, a transmembrane glycoprotein expressed on B cells, and may act through antibody-dependent cell-mediated cytotoxicity and apoptosis. It is studied in chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and peripheral T-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

TRU-016

Drug type

Fusion protein

Targets

CD37

Mechanism

Antagonist of CD37

Pathways

antibody-dependent cell-mediated cytotoxicity, apoptosis

Therapy area

Oncology

Developer

Aptevo Therapeutics (APVO)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1/2

UNII

2MZ3L2664T

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Small Lymphocytic Lymphoma RecurrentChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Non-Hodgkin's Lymphoma (NHL)Peripheral T-cell Lymphoma

More from Aptevo Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT00614042
• ClinicalTrials.gov NCT01188681
• ClinicalTrials.gov NCT01317901
• ClinicalTrials.gov NCT01644253

Updated Oct 11, 2026. Something wrong or missing? Report it on the APVO page.